The long-term outcomes of patients with untreated or undertreated venous disease are becoming increasingly well characterized through prospective studies that have followed large cohorts of patients over years and decades. Vascular specialists are using the insights from this research to sharpen their understanding of disease progression and to make more compelling arguments for early intervention to patients who might otherwise be inclined toward watchful waiting.
Studies following patients with confirmed venous insufficiency without treatment have consistently demonstrated a trajectory of progressive disease over time, with a meaningful proportion of patients developing clinically significant skin changes within five to ten years of symptom onset. The development of lipodermatosclerosis — the chronic skin and subcutaneous tissue changes caused by sustained venous hypertension — represents a point of no return in many patients, beyond which the tissue architecture is permanently altered and the risk of ulceration is substantially elevated.
The long-term outcomes of patients who develop venous ulcers are sobering. Venous ulcers, once established, have high rates of recurrence even after initial healing — studies report one-year recurrence rates of twenty to forty percent, and five-year recurrence rates of up to seventy percent without ongoing maintenance compression therapy. Each recurrence episode carries risk of wound infection, prolonged healing time, and further tissue damage that compounds with each episode. The cumulative burden over a lifetime of recurrent ulceration is substantial.
Deep vein thrombosis, even when treated and apparently resolved, carries long-term consequences that research has increasingly clarified. Post-thrombotic syndrome — a condition of chronic venous hypertension resulting from vein damage sustained during the acute thrombotic episode — develops in up to fifty percent of patients with proximal DVT, even those who receive appropriate anticoagulation therapy. Its manifestations — chronic leg pain, swelling, skin changes, and ulceration — mirror those of primary venous insufficiency and can be equally disabling.
The economic burden of untreated venous disease is also quantifiable and substantial. Venous ulcer care is enormously resource-intensive, with patients requiring frequent dressing changes, nursing visits, and specialist appointments over prolonged periods. The indirect costs of reduced productivity, impaired mobility, and recurrent hospitalization for wound infections add further to the overall economic impact. Research consistently demonstrates that the cost of treating venous disease at its early stage — with relatively simple and inexpensive interventional procedures — is substantially lower than the cost of managing the complications of untreated disease.